Business
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update
-- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the year ended December 31,
About this update from Femasys Inc.
[{"type":"image","alt":"Femasys Inc.","displaySize":"","headline":null,"caption":"Femasys Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/301b83514d43baad2f5211eaa290a825"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GL8WCCgrHOHP9r8Vdi7XpQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/301b83514d43baad2f5211eaa290a825","width":300,"height":122}},"lazy":false},{"type":"text","content":"-- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain --","length":174,"tagName":"p"},{"type":"text","content":"ATLANTA, March 27, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the year ended December 31, 2024 and provides a corporate update.","length":362,"tagName":"p"},{"type":"text","content":"Corporate Highlights from 4Q 2024 to date","length":41,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Announced FemBloc® permanent birth control (delivery system) approval in Europe; FemBloc blended polymer component successfully completed an expedited G12 Special MDR Audit for Class III devices, and the Notified Body has recommended for CE mark approval pending the final stages of European Medical Agency (EMA) review","length":319,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced partnership with CNY Fertility, national conglomerate of 11 fertility centers, to offer FemaSeed®","length":107,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced strategic distribution partnerships for FemBloc in Spain","length":71,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced peer-reviewed publication of positive safety and efficacy results from FemBloc clinical trials","length":104,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced UK and Israeli regulatory approvals for FemaSeed and two diagnostic devices","length":85,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced notices of intention to grant two new European patent ...